All articles tagged with #astrazeneca
AstraZeneca opened a new 18-story research and development center in Cambridge, Massachusetts, on Monday. The 570,000-square-foot facility will employ nearly 2,000 scientists and is part of a $1 billion investment in the state. The company aims to expand its local workforce by over 50% while focusing on oncology, obesity, and rare diseases using advanced automation and AI.
AstraZeneca has invested $2 billion in Summit Therapeutics to develop combination cancer therapies using Summit’s lead drug, ivonescimab. CEO Pascal Soriot described the bispecific antibody as the 'next generation' of cancer care, noting its ability to outperform Merck’s Keytruda in lung cancer trials. The deal grants AstraZeneca a 12% stake but leaves commercial rights with Summit. Concurrently, AstraZeneca opened a $1 billion research facility in Cambridge, Massachusetts, utilizing AI and robotics to accelerate drug discovery for obesity, cancer, and rare diseases.
AZ’s IL-33 inhibitor tozorakimab delivered meaningful reductions in COPD exacerbations in two pivotal trials (Oberon and Titania), cutting moderate/severe attacks by about 29–34% in former smokers and around 30% overall in current/former smokers. Benefits extended across eosinophil subgroups and included a mucus plug score reduction, suggesting broad, differentiated efficacy. The company has secured FDA priority review, positioning tozorakimab as a potential flagship COPD biologic as it competes with other pipeline therapies.
AstraZeneca reported positive Phase 3 results for its COPD therapy tozorakimab, showing reductions in moderate and severe flare-ups across broad patient groups, including current and former smokers and across a range of eosinophil counts, with up to 43% reductions in some subsets. The IL-33–targeting antibody is under FDA priority review with potential approval in early 2027, and AZ has lifted its peak sales forecast above $5 billion as it eyes a larger COPD biologics market beyond current options like Dupixent and Nucala.
AstraZeneca disclosed a Phase 3 failure of its ATTR-CM silencer, which produced no extra benefit for patients already on a stabilizer, a result that may tilt the market toward stabilizers and ripple through rivals like Alnylam and BridgeBio.
Bristol Myers Squibb stock rose about 4% premarket after a Financial Times report that BMS and AstraZeneca discussed a potential $400 billion merger, while AstraZeneca ADRs fell. The deal would be one of the largest in pharma history and comes as 2026 sees a wave of big M&A activity, though analysts warned mega-deals can slow R&D productivity and pipeline progress.
Reuters reports AstraZeneca and Bristol Myers Squibb held preliminary talks about a potential merger valued at about $400 billion, which would create one of the world’s largest pharma companies. The status of talks is unclear, and such a deal would face U.S. antitrust scrutiny under the Trump administration and could require divestitures. The companies’ oncology franchises are a focal point, with historical context from Bristol Myers’ Celgene deal cited in analysis.
AstraZeneca and Bristol-Myers Squibb are reportedly in talks to merge, with a combined value near $400 billion that would create one of the world's largest pharma groups; no deal terms have been disclosed and talks could stall. Such a cross-border deal would face antitrust reviews in the US, UK, and EU, with investors awaiting more detail ahead of the Q3 2026 results in late October.
UK drugmaker AstraZeneca and US rival Bristol Myers Squibb are reportedly weighing a merger valued at about $400 billion, potentially the largest deal in history. Talks have been ongoing for months with no commitment or comment from either side, and the deal would reshape both companies’ cancer-drug portfolios and strategic positioning in the pharma industry.
AstraZeneca is in talks with Bristol Myers Squibb about a potential tie-up valued at roughly $400 billion, which would create one of the world's largest drugmakers. Discussions have been ongoing and could materialize soon but may also be delayed or collapse. The deal would reinforce AstraZeneca's US-focused pivot after its NY listing, with both companies keeping comments to themselves as talks proceed.
Earnings season kicks into high gear this week, with AstraZeneca reporting on Monday as a slate of results from SK Hynix, Visa, Coca-Cola, Boeing, Ford, ExxonMobil and Chevron follow later. The focus then shifts to Big Tech on Wednesday and Thursday, with Microsoft, Meta Platforms, Apple and Amazon.com set to report after Alphabet and Tesla, helping lift the market mood. Analysts project Q2 S&P 500 earnings growth around 23.2% year over year, well above the long‑term averages, indicating continued double‑digit earnings growth for the index.
AstraZeneca and Ionis reported that their heart-disease drug Wainua failed to outperform placebo in a pivotal trial for ATTR-CM (transthyretin-mediated amyloid cardiomyopathy), not reducing cardiovascular death or clinical events, and the news pushed both companies' shares down in premarket trading.
The FDA postponed its decision on AstraZeneca’s oral breast cancer drug camizestrant after an advisory committee voted (6-3) that the treatment did not show a clinically meaningful benefit in the Serena-6 switching trial. AstraZeneca provided additional analyses requested by the agency, including circulating tumor DNA data, and the FDA is reviewing them before issuing a ruling; no new decision date has been set. Europe has given a positive opinion for camizestrant, which will be marketed as Etcamah there.
An FDA advisory panel voted 6-3 against approving AstraZeneca's oral breast cancer drug camizestrant due to concerns about trial design, sending AstraZeneca shares about 2% lower in London. While the panel did not question the drug's safety, it said the SERENA-6 results did not prove that early switching to camizestrant improves long-term survival. The company will continue working with the FDA as it reviews the application, and analysts say the setback may be more sentiment-related than a fundamental issue for the stock.
An FDA advisory panel voted 6-3 against approving AstraZeneca's oral SERD camizestrant for HR-positive, HER2-negative metastatic breast cancer with ESR1 mutations detected before progression, citing insufficient evidence of a meaningful long-term benefit and trial-design concerns (no crossover, OS data immature). Approval now seems unlikely despite a progression-free survival improvement seen in Serena-6.